Hims & Hers (HIMS) Stock Price Prediction (HIMS & HERS (HIMS) STOCK PRICE PREDICTION): Complete Guide

Investment Disclaimer: This article is for informational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions.

By the Editorial Research Team | Financial Markets Analysis | Last Updated: June 2025

Hims & Hers Health, Inc. (NYSE: HIMS) traded at approximately $20–$22 per share in mid-2025, down roughly 40–50% from its late-2024 peak after the FDA's decision to remove semaglutide from its drug shortage list reshaped the company's near-term revenue outlook. Wall Street analysts currently project a consensus 12-month price target in the range of $22–$28 for HIMS stock, according to aggregated data from MarketBeat as of June 2025.

This guide examines the HIMS stock forecast across three time horizons (2025, 2026, and 2030) using analyst consensus data, scenario-based price target tables, and a structured bull and bear case analysis. The central question for investors evaluating this Hims and Hers stock prediction is whether the company's core subscription business can absorb the revenue headwind from the semaglutide ruling while management pursues alternative growth pathways.

Contents

1. What Is Hims & Hers Health? Company Overview
2. HIMS Financial Performance: Revenue, Subscribers, and Profitability
3. HIMS Stock Price History and Key Chart Events
4. HIMS Stock Analyst Consensus and Price Targets
5. HIMS Stock Price Prediction 2025
6. HIMS Stock Price Prediction 2026
7. HIMS Stock Price Prediction 2030: Long-Term Outlook
8. Bull Case for HIMS Stock: Key Upside Catalysts
9. Bear Case for HIMS Stock: Key Downside Risks
10. HIMS vs. Competitors: Competitive Landscape
11. Is HIMS Stock a Good Investment? Valuation and Risk Assessment
12. Key Risks to Monitor for HIMS Stock
13. HIMS Stock Prediction: Frequently Asked Questions

What Is Hims & Hers Health? Company Overview

Hims & Hers Health, Inc. (NYSE: HIMS) is a direct-to-consumer (DTC) telehealth company that provides prescription and wellness treatments for hair loss, erectile dysfunction, weight management, mental health, and skincare through its subscription-based telehealth platform. The company operates in the United States and serves both men through its Hims brand and women through its Hers brand, all under the single parent entity Hims & Hers Health, Inc., headquartered in San Francisco, CA.

The DTC model means patients consult licensed clinicians online, receive prescriptions, and have medications delivered directly to their door. This structure bypasses traditional insurance networks, in-person clinic visits, and retail pharmacy queues. HIMS is primarily cash-pay, which gives it a different margin profile and regulatory exposure compared to insurance-based telehealth platforms. Subscribers pay recurring fees directly for access to the telehealth platform and prescription treatments.

HIMS's product categories span several treatment areas. Hair loss treatments, including finasteride (for male pattern baldness) and minoxidil (topical and oral), represent the company's foundational and longest-running segment with consistently high subscriber retention. Erectile dysfunction treatments, including sildenafil (generic Viagra) and tadalafil (generic Cialis), were among the first categories HIMS entered and remain a core recurring-revenue driver. Weight management became a significant growth engine in 2023 and 2024, with HIMS offering access to compounded semaglutide treatments through affiliated pharmacies. Mental health and therapy services, including online consultations and prescription management for anxiety and depression, add further diversification beyond the regulatory-sensitive weight loss segment. Skincare completes the product mix.

Revenue flows primarily through subscriptions. HIMS reports two primary subscription KPIs: total online subscribers and Monthly Online Revenue per Subscriber, or MORS. MORS measures total online revenue divided by the average subscriber count in a given period. A rising MORS indicates that subscribers are accessing more product categories or higher-value treatments over time, which signals the subscription flywheel working as intended.

Andrew Dudum co-founded Hims & Hers in 2017 and serves as CEO. His strategic commentary from quarterly earnings calls frequently shapes analyst sentiment, particularly his guidance on the post-FDA ruling product roadmap and management's plans for rebuilding the weight management segment through alternative channels. Hims & Hers went public in January 2021 via a SPAC (Special Purpose Acquisition Company) merger with Oaktree Acquisition Corp, joining a wave of de-SPAC listings during that period.

HIMS Financial Performance: Revenue, Subscribers, and Profitability

Source: Hims & Hers Health earnings releases via HIMS Investor Relations. Data reflects most recently available quarterly figures as of June 2025. Verify current figures against the latest earnings release before making investment decisions.

HIMS reported full-year 2024 revenue of approximately $1.48 billion, representing roughly 67% year-over-year growth compared to fiscal year 2023, according to the company's SEC filings on EDGAR. This growth rate positions HIMS among the fastest-growing public healthcare companies at its revenue scale, and it is the primary justification bulls use for the company's premium price-to-sales multiple.

The weight management segment, built around access to compounded semaglutide, became a major revenue driver in 2024. GLP-1 receptor agonists (a class of medications that mimic a natural hormone to regulate appetite and blood sugar) surged in cultural prominence through the "Ozempic boom," creating substantial demand for affordable weight management options. Semaglutide, the active ingredient in Ozempic and Wegovy made by Novo Nordisk, is the most prominent GLP-1 receptor agonist. HIMS accessed this market through affiliated compounding pharmacies operating under the FDA's drug shortage designation framework, a pathway disrupted in early 2025 and explained fully in the Bear Case section below.

HIMS reported approximately 2.2 million online subscribers as of Q4 2024, representing roughly 44% year-over-year growth. Subscriber count and MORS are the two metrics analysts watch most closely as leading indicators for revenue trajectory. The Q4 2024 MORS of approximately $72 per subscriber per month reflected product mix expansion driven by the high-value weight management segment. Whether MORS contracts post-FDA ruling, as semaglutide subscribers churn or shift to lower-priced core categories, is a central monitoring point for 2025.

Adjusted EBITDA (non-GAAP) represents earnings before interest, taxes, depreciation, and amortization, further adjusted for stock-based compensation and other non-cash charges. HIMS achieved adjusted EBITDA (non-GAAP) profitability in 2024, reporting approximately $58.7 million in Q4 2024 alone. This milestone matters because it signals the core business generates positive cash flow before accounting for financing costs and non-cash charges, reducing the binary risk profile associated with growth-stage companies that burn capital indefinitely. On a GAAP basis, which includes stock-based compensation as a real expense, HIMS may still report net losses in certain quarters. Investors tracking true profitability should monitor both figures.

Analyst consensus revenue estimates for FY2025 project approximately $1.6–$1.8 billion in revenue, with wider-than-usual estimate dispersion given the uncertainty around the post-FDA ruling subscriber trajectory. FY2026 consensus estimates project further growth toward $1.9–$2.2 billion, contingent on management successfully developing alternative revenue pathways. HIMS's next quarterly earnings report is expected in August 2025; that release will provide the first concrete post-ruling subscriber count data that analysts and investors are watching most closely.

HIMS Stock Price History and Key Chart Events

HIMS stock reached a 52-week high of approximately $44–$46 in late 2024, before declining to a 52-week low of approximately $18–$20 in early-to-mid 2025. This price range reflects one of the most dramatic single-catalyst corrections in recent telehealth sector history.

For long-term context, Hims & Hers went public via its SPAC merger in January 2021 at approximately $10–$11 per share. Like many de-SPAC listings of that era, HIMS traded at elevated multiples initially before declining sharply as the broader growth-stock de-rating of 2022 took effect. The stock bottomed near $2–$3 in late 2022 before beginning a multi-year recovery.

The 2024 price appreciation was driven substantially by investor enthusiasm around HIMS's entry into the weight management market. As semaglutide demand surged and HIMS scaled its compounded semaglutide program through affiliated 503A compounding pharmacies, the company reported accelerating revenue growth that justified a higher price-to-sales multiple. The stock appreciated more than 400% from its 2022 lows to its late-2024 peak.

The 2025 decline was triggered by the FDA's decision to remove semaglutide from its drug shortage list, announced in stages beginning in early 2025. Following the FDA's formal determination that the semaglutide shortage had resolved, HIMS shares declined approximately 40–50% from peak levels as investors priced in the expected impact on the weight management revenue segment. A full explanation of the regulatory mechanism behind this decline appears in the Bear Case section below.

HIMS has historically carried elevated short interest, with approximately 15–20% of its float sold short at various points in 2024–2025, according to data from Finra and Yahoo Finance. This elevated short interest creates the potential for short squeeze events when positive news triggers rapid short-covering, which has contributed to HIMS's characteristic price volatility in both directions.

HIMS Stock Analyst Consensus and Price Targets

Source: MarketBeat HIMS analyst ratings. Analyst ratings are subject to change and may be revised following earnings releases. Verify current consensus before making investment decisions.

According to MarketBeat consensus data as of June 2025, 18 analysts cover HIMS with a consensus Buy rating and an average 12-month price target of approximately $26.50. This Wall Street price target consensus projects meaningful upside from the current trading range, though the distribution of individual targets reflects genuine disagreement about the pace of post-semaglutide revenue recovery.

The rating distribution tells an informative story. Eleven Buy ratings (61% of coverage) indicate that a majority of Wall Street analysts believe HIMS will outperform the broader market over the next 12 months, based on their individual financial models and assumptions. This majority Buy stance suggests analysts broadly expect the core business to absorb the semaglutide headwind, a view that underpins the base case forecast below. The six Hold ratings reflect analysts who see the risk-reward as roughly balanced at current levels, while the single Sell rating represents the bear case view that current valuation does not adequately price in downside risk.

The spread between the most optimistic target of $40 and the most conservative of $12 is unusually wide for a single stock. It reflects genuine uncertainty about two unresolved questions: how many weight management subscribers will churn over the next several quarters, and whether HIMS successfully launches an alternative GLP-1 product pathway before FY2025 revenue guidance becomes a negative surprise. Analysts on the high end model a rapid subscriber recovery; those on the low end model sustained churn without a near-term offset.

A consensus Buy rating means the majority of covering analysts expect HIMS to outperform the broader market over the next 12 months, based on stated assumptions rather than guarantees. Analyst price targets change frequently following earnings releases and regulatory news. The figures above reflect data as of June 2025 and may not reflect subsequent revisions.

HIMS Stock Price Prediction 2025

HIMS Stock Forecast 2025: Bull, Base, and Bear Scenarios

Note: These scenarios are based on analyst consensus estimates and stated assumptions as of June 2025. They are projections, not guaranteed outcomes. Source: MarketBeat consensus data and analyst scenario modeling.

The 2025 outlook for HIMS stock turns on two variables: how many weight management subscribers cancel their subscriptions following the FDA's removal of semaglutide from the shortage list, and how quickly management can replace that revenue through alternative product pathways.

The bull scenario requires subscriber churn to be lower than bears fear. If the weight management subscriber base proves stickier than expected (because some subscribers continue paying for adjacent services, or because HIMS launches a compliant GLP-1-adjacent product relatively quickly) total revenue growth could remain in the 30%+ range even with the semaglutide segment reduced. Analysts projecting $34–$40 price targets typically model this kind of partial recovery, combined with continued momentum in the hair loss, ED, and skincare categories. The analyst consensus price target of approximately $26.50 is consistent with the upper end of the base scenario range.

The base scenario accepts moderate churn and models a business in transition. The core categories continue growing, the weight management segment contracts but does not collapse entirely, and total revenue growth decelerates but remains positive. This scenario values HIMS at a lower P/S multiple than its 2024 peak, reflecting the reduced growth trajectory.

The bear scenario requires both sustained churn and an absence of product pipeline execution. If semaglutide subscribers cancel at high rates and management cannot offer a compelling alternative by year-end 2025, total revenue growth could decelerate dramatically, pulling the P/S multiple down toward the low end of the sector range. Whether HIMS stock goes up in 2025 depends primarily on subscriber churn data from Q1 and Q2 2025 earnings releases and any product announcement regarding alternative GLP-1 pathways.

HIMS Stock Price Prediction 2026

Note: 2026 forecasts carry significant uncertainty given the evolving regulatory environment for compounded medications. These scenarios are illustrative projections, not guaranteed outcomes.

By 2026, the central question for HIMS investors will likely be resolved: whether the company successfully diversified revenue beyond compounded semaglutide and rebuilt its weight management segment through alternative product pathways.

The 2026 forecast hinges on the GLP-1 receptor agonist regulatory arc. Demand for affordable weight management treatments remains substantial regardless of the semaglutide shortage designation; the addressable market has not shrunk, only the specific legal pathway HIMS used to serve it. If HIMS executes on alternative GLP-1-related products by 2026 (whether through FDA-approved formulations, tirzepatide-related programs, or adjacent weight management categories) the bull case projects a return to stronger growth and multiple expansion. The base case assumes a gradual rebuild where core category strength sustains the business while the weight management segment finds its post-semaglutide equilibrium. The bear case reflects persistent regulatory headwinds and subscriber stagnation that leads to P/S multiple compression toward the lower end of the telehealth sector range.

HIMS Stock Price Prediction 2030: Long-Term Outlook

Five-year stock price projections carry substantial uncertainty. The 2030 HIMS stock long-term outlook depends on variables that cannot be modeled with precision today, including the long-term regulatory environment for compounded medications, the competitive response from Amazon and other technology-focused healthcare entrants, and whether HIMS successfully builds a diversified DTC health platform beyond its current product mix.

Important: 2030 price projections are highly speculative extrapolations based on current trends and stated assumptions. They are not analyst consensus estimates and carry exceptional uncertainty. Past performance does not predict future results.

The addressable market for affordable, on-demand healthcare remains large. If HIMS retains and grows its subscriber base while expanding into new condition categories and successfully navigating the GLP-1 regulatory environment, the platform economics could support substantially higher revenue by 2030.

Whether HIMS qualifies as a strong long-term investment depends on factors that will clarify over the next several quarters. Investors assessing a 2030 horizon should look for evidence of successful product diversification beyond compounded semaglutide, continued subscriber growth that validates the DTC model's durability, and progress toward GAAP profitability, which would reduce the multiple-compression risk that bears associate with pre-GAAP-profitable growth stocks. None of these constitute a guarantee, but tracking them gives a measurable framework for evaluating the long-term thesis.

The long-term bull case rests on whether the telehealth platform becomes a multi-condition health subscription that patients maintain for years across hair and sexual health, mental health, and weight management simultaneously. The bear case is that large technology players, particularly Amazon Clinic operating with Amazon Pharmacy's distribution infrastructure, replicate the DTC convenience model at scale and undercut HIMS's pricing power over time. Investors seeking a framework for long-horizon growth stock analysis may find the approach in our Tesla stock price prediction 2030 scenario guide a useful structural reference.

Bull Case for HIMS Stock: Key Upside Catalysts

The bull case for HIMS starts with a single hard data point: 67% revenue growth in 2024, which places the company well above peers at similar scale. That growth rate is what justifies the premium P/S multiple, and bulls argue the core subscription model can sustain meaningful growth even after the semaglutide headwind is absorbed. Four additional arguments reinforce that thesis.

1. Subscription Model Durability Across Non-Regulatory Categories

Hair loss treatments (finasteride, minoxidil) and erectile dysfunction treatments (sildenafil, tadalafil) are generic medications with no equivalent FDA drug shortage risk to the semaglutide situation. These categories generate high-retention recurring revenue at attractive margins and represent the original foundation of HIMS's business model. Mental health subscriptions, including online therapy and psychiatric medication management, add diversification beyond both the regulatory-vulnerable weight management segment and the traditionally male-skewing core categories.

2. Adjusted EBITDA Profitability Reduces Binary Risk

HIMS reported approximately $171 million in adjusted EBITDA (non-GAAP) for full-year 2024, demonstrating that the core business generates positive cash flow before non-cash charges. This profitability milestone distinguishes HIMS from early-stage growth companies that depend on capital raises to survive. Even in the bear scenario for 2025, the probability of an existential capital crisis is low, a meaningful improvement in the risk profile compared to where HIMS stood two to three years ago.

3. GLP-1 Market Demand Persists Beyond the Shortage Designation

Consumer demand for affordable GLP-1 receptor agonist treatments has not diminished with the semaglutide shortage removal. The patient population seeking these treatments remains large, and HIMS has the brand recognition, subscriber acquisition infrastructure, and telehealth platform to pursue alternative pathways (FDA-approved GLP-1 formulations, compounding under different regulatory conditions, or adjacent obesity care products). Bulls argue this long-term GLP-1 market opportunity is not fully reflected in current consensus price targets, which price in significant semaglutide headwind but limited recovery optionality.

4. DTC Platform Creates Sustainable Cross-Sell Economics

HIMS's multi-condition telehealth platform allows a single subscriber to access treatments for multiple conditions simultaneously, increasing MORS over time. Platform stickiness, driven by behavioral inertia and the friction of switching to a new care provider, reduces churn risk in the core categories not subject to the FDA ruling. The more conditions a subscriber manages through HIMS, the less likely they are to cancel a subscription for a single category.

5. Recovery Potential from Elevated Short Interest

HIMS has historically carried elevated short interest. If subscriber churn from the semaglutide segment proves lower than feared, positive earnings surprises could trigger rapid short-covering rallies, amplifying any upward price movement on good news.

Whether these catalysts materialize on the timeline bulls project depends on management execution, regulatory clarity, and competitive dynamics, none of which are guaranteed.

Bear Case for HIMS Stock: Key Downside Risks

The bear case against HIMS stock centers on a single regulatory event that eliminated a major revenue pathway: the FDA's removal of semaglutide from its drug shortage list, which stripped HIMS of the legal basis for offering compounded semaglutide to patients at prices well below the branded alternatives.

The FDA Semaglutide Ruling Explained

The FDA maintains a Drug Shortage Database under 21 U.S.C. §356c, which tracks pharmaceutical compounds facing supply constraints. When a drug appears on this shortage list, licensed compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act are permitted to prepare that drug for individual patients under a valid prescription. This is not a regulatory shortcut; it is an established legal framework designed to ensure patient access to medications that cannot otherwise be obtained in sufficient supply.

Semaglutide is the active pharmaceutical ingredient in Ozempic (FDA-approved by Novo Nordisk for type 2 diabetes management) and Wegovy (FDA-approved by Novo Nordisk for chronic weight management). Both products experienced supply shortages beginning around 2022–2023 as demand from the "Ozempic boom" far outpaced Novo Nordisk's manufacturing capacity. The FDA placed semaglutide on its shortage list, which enabled Section 503A compounding pharmacies to legally prepare compounded semaglutide formulations for patients with valid prescriptions. HIMS operated as or partnered with these compounding pharmacies, offering compounded semaglutide at prices typically in the range of $150–$300 per month, compared to $800–$1,000 or more per month for branded Ozempic or Wegovy without insurance coverage.

The FDA determined in early 2025 that the semaglutide shortage had resolved and formally removed semaglutide from the drug shortage list. This removal eliminated the legal basis for Section 503A compounding pharmacies to prepare semaglutide for new patients using the shortage designation pathway. HIMS can no longer rely on this pathway to offer compounded semaglutide at scale to new subscribers. For the most current semaglutide shortage status, investors can verify directly at the FDA Drug Shortage Database.

The financial impact is material. The weight management segment had grown to represent an estimated 30–40% of HIMS's total revenue by late 2024, according to analyst estimates, making the semaglutide ruling the most significant single business disruption in the company's public history. Following the FDA's announcement, HIMS shares declined approximately 40–50% from their late-2024 highs as investors priced in the expected revenue contraction.

The FDA did not ban semaglutide. Branded Ozempic and Wegovy remain available via prescription through traditional channels. The ruling affected HIMS's specific 503A compounding pharmacy pathway, a distinction that matters for evaluating the investment thesis accurately. Users who encountered headlines describing a "semaglutide ban" are working from an imprecise framing of what occurred.

Remaining Bear Arguments:

1. Subscriber Churn Risk If weight management subscribers cancel following the loss of compounded semaglutide access and core-category subscriber acquisition cannot replace them in volume, total online subscriber count could decline year-over-year. A declining subscriber count is the single most negative signal the investment thesis could receive, as subscriber growth has been the primary leading indicator for HIMS revenue. Q1 and Q2 2025 earnings releases will provide the first concrete data on churn magnitude.

2. Teladoc Sector Precedent Teladoc Health (NYSE: TDOC), once the market leader in telehealth, reached a P/S multiple above 20x during pandemic-era enthusiasm before declining over 90% from its highs as growth decelerated. Bears cite the Teladoc trajectory as a direct warning for HIMS investors: high-multiple telehealth stocks have historically experienced severe multiple compression when revenue growth disappoints, and HIMS's growth rate may be about to disappoint for the first time.

3. P/S Valuation Premium Risk At its late-2024 peak, HIMS traded at approximately 10–12x trailing revenue, a significant premium to Teladoc's current roughly 1–2x P/S ratio. Even after the 2025 correction, HIMS may still trade at a premium multiple that does not adequately price in the revenue uncertainty. If 2025 revenue growth decelerates toward 10–15%, bears argue the appropriate P/S multiple is substantially lower than current trading levels.

4. Amazon Clinic as Structural Competitive Threat Amazon Clinic leverages Amazon Pharmacy's distribution infrastructure to offer telehealth consultations and prescription delivery that directly overlaps with HIMS's service model. Amazon's distribution scale, brand trust, and customer acquisition efficiency represent a structural competitive risk that HIMS cannot easily replicate. This is a long-term threat rather than an immediate earnings catalyst, but it represents an overhang on HIMS's long-term valuation ceiling.

5. GAAP Profitability Gap HIMS's adjusted EBITDA (non-GAAP) profitability excludes stock-based compensation, which is a real and significant expense for growth technology companies. On a GAAP basis, HIMS may still report net losses in quarters where revenue disappoints or stock-based compensation expense increases. Investors who evaluate profitability on a GAAP basis view this gap as a material concern and apply a discount to the adjusted metrics HIMS management highlights.

Bears present a serious case, but whether these risks are fully priced into the current stock price is the central debate between HIMS bulls and bears.

HIMS vs. Competitors: Competitive Landscape

Sources: HIMS earnings releases via investors.forhims.com; TDOC earnings releases via ir.teladochealth.com; P/S ratios from Yahoo Finance as of June 2025. Verify figures against current filings.

The most important structural distinction between HIMS and Teladoc Health (NYSE: TDOC) is the business model. HIMS operates a cash-pay direct-to-consumer model, while Teladoc primarily serves employers and insurance providers through B2B contracts. This structural difference means they serve different customer channels, face different competitive dynamics, and carry different regulatory profiles. The two companies are telehealth sector peers for valuation comparison purposes, but they do not compete for the same customers in any direct way.

Teladoc's stock trajectory is a double-edged reference for HIMS investors. Bears cite Teladoc's decline from a peak near $300 per share to below $10 as evidence that high-multiple telehealth stocks face severe multiple compression when growth disappoints. Bulls counter that HIMS's DTC cash-pay model, positive adjusted EBITDA trajectory, and significantly higher growth rate distinguish it structurally from the Teladoc narrative. HIMS at a 4–6x P/S ratio is a substantially different proposition than Teladoc at 20x+ P/S during 2021.

Roman Health (Ro), a private DTC competitor targeting men's health (ED, hair loss, and telehealth), confirms that competitive pressure exists in HIMS's core segment. Ro remains private, limiting direct financial comparison, but its continued operation as a well-funded competitor indicates the DTC men's health market is actively contested.

Amazon Clinic, backed by Amazon Pharmacy's fulfillment infrastructure, represents the big-technology competitive risk that sector investors monitor most closely. Amazon's scale, customer trust, and pharmacy infrastructure give it structural advantages HIMS cannot easily match. The near-term threat remains limited, but the long-term competitive ceiling it places on DTC telehealth valuations is a factor sector-focused investors should weigh.

Is HIMS Stock a Good Investment? Valuation and Risk Assessment

Whether HIMS stock represents an attractive investment depends on how an individual investor weighs the company's demonstrated revenue growth trajectory against the regulatory uncertainty created by the FDA semaglutide ruling and the open question of post-semaglutide revenue recovery.

Risk Profile Summary:

• Classification: High Risk / High Reward Growth Stock
• Primary Upside Catalyst: Subscriber growth resilience and successful development of alternative weight management revenue pathways post-semaglutide ruling
• Primary Downside Risk: Weight management subscriber churn exceeds analyst expectations with no near-term replacement revenue; P/S multiple compresses further
• Suited for investors who: Have a multi-year time horizon, can tolerate 30–50% drawdowns without forced selling, and are comfortable with companies reporting adjusted EBITDA profitability but not yet consistent GAAP net income

As of June 2025, Wall Street analysts hold a consensus Buy rating for HIMS with an average 12-month price target of approximately $26.50, according to MarketBeat data. This consensus implies meaningful upside from current trading levels, though the wide target range ($12–$40) reflects how much uncertainty remains in the near-term outlook.

HIMS Valuation: Is the P/S Multiple Justified?

The price-to-sales (P/S) ratio measures a company's market capitalization divided by its annual revenue. For growth companies like HIMS that have not yet achieved consistent GAAP net income profitability, P/S is a more appropriate valuation framework than the price-to-earnings (P/E) ratio, because earnings-based multiples become unreliable or undefined when GAAP net income is negative or near zero.

Source: Yahoo Finance / Macrotrends as of June 2025. Verify before use.

Bulls argue HIMS's P/S premium relative to Teladoc is justified by the growth rate differential. A company growing revenue at 67% annually commands a higher revenue multiple than a company with flat or declining revenue. The question is whether 2025 and 2026 growth will decelerate enough to compress the multiple toward sector averages. Bears argue the current P/S of 4–6x is still elevated given the semaglutide headwind, particularly if 2025 revenue growth prints well below consensus expectations.

Before making any investment decision about HIMS, a reasonable investor should weigh the following factors:

• Risk tolerance: HIMS is a high-risk growth stock that can move 20–30% in a single day on earnings or regulatory news, and position sizing should reflect that volatility.
• Time horizon: The 2025 forecast carries more uncertainty than normal due to the FDA ruling, making a shorter holding period more speculative than a multi-year outlook.
• FDA resolution visibility: Monitoring Q1 and Q2 2025 earnings for subscriber count data and management guidance on alternative product pathways is the most actionable near-term signal.
• Subscriber trajectory: Declining subscriber counts are a red flag; sustained growth or stability is the baseline assumption in analyst bull and base cases.
• Portfolio sizing: Given the single-stock risk concentration, HIMS should represent a position sized appropriately for a high-conviction, high-risk growth allocation rather than a core holding.

This analysis is for informational purposes only and does not constitute personalized financial advice. Investors should conduct their own due diligence and consult a qualified financial advisor before making investment decisions.

Key Risks to Monitor for HIMS Stock

Investors evaluating HIMS stock should track the following risk categories, each of which could materially affect the company's revenue trajectory and stock price in 2025 and beyond.

1. Regulatory Risk (Primary)

The FDA's removal of semaglutide from its drug shortage list is the most immediate active risk. Additional FDA decisions regarding pharmaceutical compounding rules could create further headwinds if applied to other medications HIMS compounds or distributes. HIMS's business model is structurally sensitive to FDA drug shortage designation status, and any future removal of a drug from the shortage list that has become a significant revenue driver would repeat the 2025 semaglutide dynamic.

2. Competitive Risk

Amazon Clinic, backed by Amazon Pharmacy's distribution infrastructure, is actively building its DTC telehealth footprint. If Amazon accelerates its prescription medication delivery program in HIMS's core categories, it could pressure subscriber acquisition costs and retention rates over time. This is a long-duration risk rather than an immediate 2025 catalyst, but the trajectory of Amazon's healthcare investments warrants monitoring.

3. Profitability Risk

HIMS reports adjusted EBITDA (non-GAAP) profitability but continues to report GAAP net losses in some periods due to stock-based compensation expenses. Stock-based compensation represents real dilution to shareholders not captured in the adjusted metric. Investors focused on GAAP profitability should monitor the gap between adjusted EBITDA and GAAP net income and the timeline for HIMS to achieve sustainable GAAP break-even.

4. Valuation and Macro Risk

HIMS's P/S multiple of approximately 4–6x is sensitive to both revenue growth deceleration and the broader interest rate environment. Growth stocks with elevated P/S multiples historically face multiple compression when interest rates rise or when the growth narrative deteriorates. If 2025 revenue growth prints materially below the consensus 15–25% range, the stock may face additional P/S compression beyond what has already occurred.

5. Subscriber Churn Risk

The post-FDA ruling subscriber trajectory is the single most important monitoring variable for 2025. A decline in total online subscribers (HIMS's primary KPI) would be a significant negative signal for the investment case, as all revenue and MORS growth models assume at minimum subscriber stability. HIMS's short interest of approximately 15–20% of float (source: Finra/Yahoo Finance, as of mid-2025) adds volatility in both directions, with short-covering rallies amplifying upward moves on positive subscriber data while confirmation of churn concerns can accelerate selling pressure.

HIMS Stock Prediction: Frequently Asked Questions

What is the HIMS stock price prediction for 2025?

Based on analyst consensus data from MarketBeat as of June 2025, the 12-month price target for HIMS stock averages approximately $26.50, with individual analyst targets ranging from $12 to $40. The base scenario in this guide projects a year-end 2025 range of $24–$30, assuming moderate subscriber churn and continued core category growth. See the full 2025 scenario analysis above for bull, base, and bear projections with stated assumptions. These are projections, not guaranteed outcomes.

What is the analyst price target for HIMS stock?

As of June 2025, 18 analysts tracked by MarketBeat hold a consensus Buy rating on HIMS with an average 12-month price target of approximately $26.50. Of those analysts, 11 rate HIMS a Buy, 6 a Hold, and 1 a Sell. The most optimistic individual analyst target is $40; the most conservative is $12. Analyst ratings change frequently following earnings releases and regulatory news; verify current consensus at MarketBeat before using these figures for investment decisions.

Is Hims & Hers stock a good buy?

This article does not provide personalized investment advice. According to MarketBeat consensus data as of June 2025, 11 of 18 covering analysts rate HIMS a Buy. The bull case points to the company's demonstrated 67% revenue growth in 2024, positive adjusted EBITDA (non-GAAP) profitability, and the long-term GLP-1 market opportunity. The bear case centers on subscriber churn risk following the FDA semaglutide ruling and the potential for P/S multiple compression if 2025 revenue growth disappoints. Whether HIMS aligns with your portfolio depends on your individual risk tolerance, investment timeline, and financial goals.

Why did HIMS stock drop?

The primary catalyst for HIMS's 2025 stock decline was the FDA's removal of semaglutide from its drug shortage list in early 2025. This decision eliminated the legal pathway under Section 503A of the Federal Food, Drug, and Cosmetic Act that allowed HIMS's affiliated compounding pharmacies to produce and dispense compounded semaglutide formulations. Investors priced in the expected revenue impact from HIMS's weight management segment, which had grown to represent approximately 30–40% of total revenue, and the stock declined approximately 40–50% from its late-2024 peak.

How does FDA regulation affect HIMS stock?

HIMS's compounding pharmacy business model is directly sensitive to FDA drug shortage designations. When a drug appears on the FDA shortage list, licensed Section 503A compounding pharmacies can legally produce it for patients with valid prescriptions; when it is removed from the list, that legal basis disappears. The semaglutide removal in early 2025 was the most significant FDA regulatory event in HIMS's public market history. Future FDA decisions about the shortage status of other compounded medications in HIMS's portfolio could create similar revenue impacts, making regulatory monitoring an ongoing requirement for HIMS investors.

What happened to HIMS stock after the FDA semaglutide ruling?

Following the FDA's formal determination that the semaglutide shortage had resolved, announced in stages in early 2025, HIMS shares declined approximately 40–50% from their late-2024 highs near $44–$46, settling in the $18–$22 range through mid-2025. Investors interpreted the ruling as a direct threat to the weight management revenue segment that had driven HIMS's 2024 growth acceleration. See the full stock price history section above for complete price context.

Does Hims & Hers make a profit?

Hims & Hers has achieved adjusted EBITDA (non-GAAP) profitability, reporting approximately $171 million in adjusted EBITDA for full-year 2024, which represents a margin of roughly 11–12%. Adjusted EBITDA (non-GAAP) excludes stock-based compensation and other non-cash charges. On a GAAP basis, which includes these real expenses, HIMS may report net losses in quarters where stock-based compensation is significant. Most investors tracking HIMS's profitability trajectory focus on the adjusted EBITDA trend as the leading operational indicator, but both figures matter for a complete picture.

How many subscribers does Hims & Hers have?

Hims & Hers reported approximately 2.23 million online subscribers as of Q4 2024, according to the company's earnings release via investors.forhims.com, representing roughly 44% year-over-year growth. Online subscriber count is one of HIMS's two primary KPIs alongside MORS and serves as the leading indicator for future revenue growth. Subscriber count data for 2025 quarters will be the most closely watched metric for assessing the impact of the FDA semaglutide ruling on business performance.

What is the HIMS stock price prediction for 2030?

Five-year projections for HIMS carry substantial uncertainty and should be treated as scenario illustrations rather than forecasts. The 2030 bull case in this guide projects a range of $80–$120 if HIMS successfully builds a diversified DTC health platform with multiple product categories and strong subscriber growth. The base case projects $35–$55 with moderate sustained growth. The bear case projects $8–$15 if regulatory headwinds persist and competitive pressures erode HIMS's market position. See the full long-term outlook section above for stated assumptions behind each scenario.

Who are HIMS's biggest competitors?

HIMS's primary competitors include Teladoc Health (NYSE: TDOC), the largest publicly traded telehealth company by revenue (though structurally distinct as a B2B insurance-based platform rather than a direct consumer competitor); Roman Health (Ro), a private DTC men's health competitor targeting ED and hair loss; and Amazon Clinic, which leverages Amazon Pharmacy to offer telehealth consultations and prescription delivery that directly overlaps with HIMS's service model. See the competitive comparison section above for a structured side-by-side analysis of HIMS versus Teladoc.

Will HIMS stock go up?

Whether HIMS stock rises depends on several variables analysts are actively monitoring: the rate of subscriber churn following the FDA semaglutide ruling, the pace of revenue recovery through alternative product pathways, management's ability to sustain core category growth in its established subscription segments, and broader market conditions affecting growth stock valuations. Analyst consensus as of June 2025 projects a price target of approximately $26.50, representing roughly 20–35% upside from the current trading range, though price projections carry significant uncertainty and are not guaranteed outcomes. This is not a prediction and should not be treated as investment advice.

Related Reading

• AMC Stock Forecast: A Scenario Framework for Price Ranges, Drivers and Risk
• Nvidia (NVDA) Stock Price Prediction 2030 for Beginners
• Tesla Stock Price Prediction 2030 (TSLA): An Illustrative Beginner-Friendly Outlook

Investment Disclaimer

This article is for informational and educational purposes only. Nothing in this article constitutes personalized financial, investment, legal, or tax advice. The analysis, price targets, and scenarios presented are based on publicly available information and analyst consensus data as of the dates cited; they do not represent a recommendation to buy, sell, or hold any security.

Hims & Hers Health, Inc. (NYSE: HIMS) is a publicly traded security subject to significant price volatility and investment risk. All forward-looking price projections presented in this article are speculative estimates based on stated assumptions and may not be realized. Actual stock performance may differ materially from any projection presented here.

The publisher of this article may or may not hold positions in securities mentioned. Past performance of any security, including HIMS, does not guarantee future results. Investors should conduct their own independent research, review the most current HIMS earnings releases and SEC filings at HIMS Investor Relations and SEC EDGAR, and consult a qualified financial advisor before making any investment decision.

Analyst consensus data cited in this article is sourced from MarketBeat HIMS analyst ratings as of June 2025 and is subject to change. FDA regulatory information referenced in this article should be verified against the FDA Drug Shortage Database for the most current status.